

Taro Kishi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6815460/publications.pdf>

Version: 2024-02-01

158
papers

4,184
citations

101543

36
h-index

149698

56
g-index

159
all docs

159
docs citations

159
times ranked

5828
citing authors

#	ARTICLE	IF	CITATIONS
1	Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study. <i>Psychiatry and Clinical Neurosciences</i> , 2022, 76, 22-31.	1.8	4
2	Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials. <i>Molecular Psychiatry</i> , 2022, 27, 1136-1144.	7.9	46
3	Observations on the results of a systematic review and network meta-analysis of double-blind randomized, placebo-controlled trials to examine early onset of response to pharmacological intervention for bipolar depression. <i>Bipolar Disorders</i> , 2022, 24, 330-331.	1.9	0
4	Early improvement as a predictor of response to blonanserin transdermal patch in patients with schizophrenia. <i>Schizophrenia Research</i> , 2022, 240, 231-232.	2.0	2
5	Volume of Amygdala Subregions and Plasma Levels of Brain-Derived Neurotrophic Factor and Cortisol in Patients with s/s Genotype of Serotonin Transporter Gene Polymorphism of First-Episode and Drug-Naive Major Depressive Disorder: An Exploratory Study. <i>Neurology International</i> , 2022, 14, 378-390.	2.8	1
6	Early improvement as a predictor of later response to lurasidone in schizophrenia from Japan trials: A diagnostic test. <i>Psychiatry and Clinical Neurosciences</i> , 2022, 76, 401-402.	1.8	2
7	Mitochondrial modulators for obsessive-compulsive and related disorders: a systematic review and meta-analysis. <i>Translational Psychiatry</i> , 2022, 12, .	4.8	2
8	Lemborexant for insomnia in adults with psychiatric disorders: A 1-week, open-label study. , 2022, 1, .		2
9	Recurrence rates in stable bipolar disorder patients after drug discontinuation <i>v.</i> drug maintenance: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2021, 51, 2721-2729.	4.5	19
10	Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials. <i>Molecular Psychiatry</i> , 2021, 26, 4146-4157.	7.9	79
11	Association between discontinuation due to withdrawal of consent and use of long-acting injectable antipsychotics: A meta-analysis of randomized trials for schizophrenia. <i>Journal of Psychiatric Research</i> , 2021, 132, 144-150.	3.1	2
12	Body composition in Japanese patients with psychiatric disorders: A cross-sectional study. <i>Neuropsychopharmacology Reports</i> , 2021, 41, 117-121.	2.3	2
13	Effects of a conventional mood stabilizer alone or in combination with second-generation antipsychotics on recurrence rate and discontinuation rate in bipolar I disorder in the maintenance phase: A systematic review and meta-analysis of randomized, placebo-controlled trials. <i>Bipolar Disorders</i> , 2021, 23, 789-800.	1.9	8
14	Recurrence Rates in Stable Bipolar Disorder Patients after Drug Discontinuation versus Drug Maintenance: A Systematic Review and Meta-analysis â€“ Corrigendum. <i>Psychological Medicine</i> , 2021, 51, 1-1.	4.5	2
15	Melatonin receptor agonists for bipolar mania: A systematic review and meta-analyses of double-blind randomized placebo-controlled trials. <i>Bipolar Disorders</i> , 2021, 23, 301-302.	1.9	2
16	Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan. <i>Journal of Psychiatric Research</i> , 2021, 138, 444-452.	3.1	11
17	Duration of long-acting injectable antipsychotic treatment and reasons for its discontinuation: A chart review of patients with schizophrenia. <i>Psychiatry and Clinical Neurosciences</i> , 2021, 75, 240-241.	1.8	1
18	Omega-3 fatty acids for treating residual depressive symptoms in adult patients with bipolar disorder: A systematic review and meta-analysis of double-blind randomized, placebo-controlled trials. <i>Bipolar Disorders</i> , 2021, 23, 730-731.	1.9	7

#	ARTICLE	IF	CITATIONS
19	Outcomes of patients with schizophrenia who discontinued long-acting injectable antipsychotic therapy due to adverse events: A chart review. <i>Neuropsychopharmacology Reports</i> , 2021, 41, 422-425.	2.3	2
20	Differences in the incidence of lurasidone adverse events between depressive disorders and schizophrenia in double-blind, randomized, placebo-controlled trials: a meta-analysis. <i>Psychopharmacology</i> , 2021, 238, 3585-3593.	3.1	0
21	Evidence-based insomnia treatment strategy using novel orexin antagonists: A review. <i>Neuropsychopharmacology Reports</i> , 2021, 41, 450-458.	2.3	14
22	<p>Association of Serum Kynurenine Levels and Neural Networks in Patients with First-Episode, Drug-Naïve Major Depression: A Source-Based Morphometry Study</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 2569-2577.	2.2	3
23	Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta-analysis of phase 3 trials in Japan. <i>Neuropsychopharmacology Reports</i> , 2020, 40, 314-322.	2.3	7
24	N-acetylcysteine as an adjunctive treatment for bipolar depression and major depressive disorder: a systematic review and meta-analysis of double-blind, randomized placebo-controlled trials. <i>Psychopharmacology</i> , 2020, 237, 3481-3487.	3.1	23
25	Factors associated with discontinuation in the drug and placebo groups of trials of second generation antipsychotics for acute schizophrenia: A meta-regression analysis. <i>Journal of Psychiatric Research</i> , 2020, 130, 240-246.	3.1	4
26	Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in Japan. <i>Neuropsychopharmacology Reports</i> , 2020, 40, 417-422.	2.3	4
27	Lemborexant vs suvorexant for insomnia: A systematic review and network meta-analysis. <i>Journal of Psychiatric Research</i> , 2020, 128, 68-74.	3.1	58
28	Vortioxetine vs placebo in major depressive disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled, phase 3 trials in Japan. <i>Psychiatry and Clinical Neurosciences</i> , 2020, 74, 330-332.	1.8	0
29	Blonanserin patch vs. Other Antipsychotics for Acute Schizophrenia: A Systematic Review of Double-blind, Randomized, Placebo-controlled, Phase 3 Trials in Japan. <i>Pharmacopsychiatry</i> , 2020, 53, 122-132.	3.3	2
30	Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis. <i>Psychopharmacology</i> , 2020, 237, 1459-1470.	3.1	16
31	Effect of discontinuation <i>v.</i> maintenance of antipsychotic medication on relapse rates in patients with remitted/stable first-episode psychosis: a meta-analysis. <i>Psychological Medicine</i> , 2019, 49, 772-779.	4.5	36
32	Quetiapine extended-release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis. <i>Neuropsychopharmacology Reports</i> , 2019, 39, 256-259.	2.3	4
33	Suvorexant for insomnia in patients with psychiatric disorder: A 1-week, open-label study. <i>Neuropsychopharmacology Reports</i> , 2019, 39, 252-255.	2.3	10
34	<p>COMT polymorphism regulates the hippocampal subfield volumes in first-episode, drug-naïve patients with major depressive disorder</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 1537-1545.	2.2	11
35	<p>Melatonin receptor agonistsâ€”ramelteon and melatoninâ€”for bipolar disorder: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 1479-1486.	2.2	16
36	<p>A single-nucleotide polymorphism influences brain morphology in drug-naïve patients with major depressive disorder</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2425-2432.	2.2	9

#	ARTICLE	IF	CITATIONS
37	<p>Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites</p>. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2655-2661.	2.2	7
38	Comparison of quetiapine immediate- and extended-release formulations for bipolar depression: A systematic review and network meta-analysis of double-blind, randomized placebo-controlled trials. Journal of Psychiatric Research, 2019, 115, 121-128.	3.1	6
39	Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design. Neuropsychopharmacology Reports, 2019, 39, 241-246.	2.3	10
40	<p>Genetic effects on white matter integrity in drug-naïve patients with major depressive disorder: a diffusion tensor imaging study of 17 genetic loci associated with depressive symptoms</p>. Neuropsychiatric Disease and Treatment, 2019, Volume 15, 375-383.	2.2	29
41	Response to the Letter from Dr. Jacob Peedicayil. Psychopharmacology, 2019, 236, 1403-1404.	3.1	0
42	Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia: An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pharmacopsychiatry, 2019, 52, 52-62.	3.3	22
43	Response to the letter from Dr. Kim and colleagues. Psychiatry Research, 2018, 263, 291-292.	3.3	0
44	Statin add-on therapy in the antipsychotic treatment of schizophrenia: A meta-analysis. Psychiatry Research, 2018, 260, 41-47.	3.3	18
45	Memantine treatment for Japanese patients with moderate to severe Alzheimer’s disease: a meta-analysis of double-blind, randomized, placebo-controlled trials. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2915-2922.	2.2	4
46	Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2519-2530.	2.2	11
47	The efficacy and safety of memantine for the treatment of Alzheimer’s disease. Expert Opinion on Drug Safety, 2018, 17, 1053-1061.	2.4	74
48	Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: a systematic review and meta-analysis. Psychopharmacology, 2018, 235, 2303-2314.	3.1	21
49	Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis. International Journal of Neuropsychopharmacology, 2018, 21, 748-757.	2.1	19
50	Serum Brain-Derived Neurotrophic Factor, and Plasma Catecholamine Metabolites in People with Major Depression: Preliminary Cross-Sectional Study. Frontiers in Psychiatry, 2018, 9, 52.	2.6	12
51	Combination Therapy of Serotonin Reuptake Inhibitors and Memantine for Obsessive–Compulsive Disorder: A Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials. Journal of Alzheimer's Disease, 2018, 64, 43-48.	2.6	11
52	Efficacy and tolerability of Z-drug adjunction to antidepressant treatment for major depressive disorder: a systematic review and meta-analysis of randomized controlled trials. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 149-161.	3.2	9
53	A Meta-Analysis of Memantine for Depression. Journal of Alzheimer's Disease, 2017, 57, 113-121.	2.6	41
54	Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis. Psychopharmacology, 2017, 234, 2113-2125.	3.1	36

#	ARTICLE	IF	CITATIONS
55	Short-term adjunct of topiramate to antipsychotics in schizophrenia improves the psychopathology and has weight maintenance. <i>Evidence-Based Mental Health</i> , 2017, 20, 61-61.	4.5	0
56	Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 401-425.	2.6	158
57	Voxel-based morphometric brain comparison between healthy subjects and major depressive disorder patients in Japanese with the s/s genotype of 5-HTTLPR. <i>Scientific Reports</i> , 2017, 7, 3931.	3.3	19
58	Response to the letter from Dr. Veerman and colleagues. <i>Psychopharmacology</i> , 2017, 234, 3537-3538.	3.1	0
59	Z-drug for schizophrenia: A systematic review and meta-analysis. <i>Psychiatry Research</i> , 2017, 256, 365-370.	3.3	9
60	The effects of memantine on behavioral disturbances in patients with Alzheimer's disease: a meta-analysis. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 1909-1928.	2.2	43
61	Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 1281-1302.	2.2	19
62	Brain-Derived Neurotrophic Factor and Major Depressive Disorder: Evidence from Meta-Analyses. <i>Frontiers in Psychiatry</i> , 2017, 8, 308.	2.6	139
63	A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 3041-3049.	2.2	10
64	Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 3221-3236.	2.2	14
65	Relationship between G1287A of the NET Gene Polymorphisms and Brain Volume in Major Depressive Disorder: A Voxel-Based MRI Study. <i>PLoS ONE</i> , 2016, 11, e0150712.	2.5	18
66	Routine use of antipsychotics to prevent or treat delirium is not recommended. <i>Evidence-Based Mental Health</i> , 2016, 19, 123-123.	4.5	0
67	Mortality Risk Associated With Long-acting Injectable Antipsychotics: A Systematic Review and Meta-analyses of Randomized Controlled Trials. <i>Schizophrenia Bulletin</i> , 2016, 42, 1438-1445.	4.3	37
68	Yokukansan in the Treatment of Behavioral and Psychological Symptoms of Dementia: An Updated Meta-Analysis of Randomized Controlled Trials. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 635-643.	2.6	37
69	Long-acting injectable antipsychotics for the prevention of relapse in patients with recent-onset psychotic disorders: A systematic review and meta-analysis of randomized controlled trials. <i>Psychiatry Research</i> , 2016, 246, 750-755.	3.3	36
70	Lack of improvement at week 2 predicts later antipsychotic non-response in people with acute exacerbations of schizophrenia or schizophrenia-like psychosis. <i>Evidence-Based Mental Health</i> , 2016, 19, 61-61.	4.5	0
71	Long-Acting Injectable Antipsychotics for Prevention of Relapse in Bipolar Disorder: A Systematic Review and Meta-Analyses of Randomized Controlled Trials. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw038.	2.1	54
72	Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw086.	2.1	36

#	ARTICLE	IF	CITATIONS
73	Antipsychotic medications for the treatment of delirium: a systematic review and meta-analysis of randomised controlled trials. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 767-774.	1.9	87
74	Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 439-450.	3.2	39
75	Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 419.	2.2	8
76	Memantine Monotherapy for Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0123289.	2.5	185
77	Relationship between a BDNF gene polymorphism and the brain volume in treatment-naïve patients with major depressive disorder: A VBM analysis of brain MRI. <i>Psychiatry Research - Neuroimaging</i> , 2015, 233, 120-124.	1.8	44
78	Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 259-268.	3.2	38
79	A cross-sectional survey to investigate the prevalence of pain in Japanese patients with major depressive disorder and schizophrenia. <i>Comprehensive Psychiatry</i> , 2015, 59, 91-97.	3.1	13
80	Intramuscular olanzapine for agitated patients: A systematic review and meta-analysis of randomized controlled trials. <i>Journal of Psychiatric Research</i> , 2015, 68, 198-209.	3.1	49
81	Combination Therapy with Cholinesterase Inhibitors and Memantine for Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, .	2.1	67
82	Memantine for Lewy Body Disorders: Systematic Review and Meta-Analysis. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 373-383.	1.2	27
83	Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. <i>PLoS ONE</i> , 2015, 10, e0136910.	2.5	67
84	Effect of Scopolamine Butylbromide on Clozapine-induced Hypersalivation in Schizophrenic Patients: A Case Series. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015, 13, 109-112.	2.0	14
85	Cardiometabolic Risks of Blonanserin and Perospirone in the Management of Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>PLoS ONE</i> , 2014, 9, e88049.	2.5	19
86	Early prediction of blonanserin response in Japanese patients with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1861.	2.2	6
87	The position of blonanserin as a treatment for schizophrenia. <i>Asia-Pacific Psychiatry</i> , 2014, 6, 462-462.	2.2	3
88	A meta-analysis of inositol for depression and anxiety disorders. <i>Human Psychopharmacology</i> , 2014, 29, 55-63.	1.5	59
89	Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. <i>Human Psychopharmacology</i> , 2014, 29, 483-491.	1.5	60
90	COMT Val158Met, but not BDNF Val66Met, is associated with white matter abnormalities of the temporal lobe in patients with first-episode, treatment-naïve major depressive disorder: a diffusion tensor imaging study. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1183.	2.2	18

#	ARTICLE	IF	CITATIONS
91	Serum proBDNF/BDNF and response to fluvoxamine in drug-naïve first-episode major depressive disorder patients. <i>Annals of General Psychiatry</i> , 2014, 13, 19.	2.7	25
92	Selective Serotonin 3 Receptor Antagonist Treatment for Schizophrenia: Meta-analysis and Systematic Review. <i>NeuroMolecular Medicine</i> , 2014, 16, 61-69.	3.4	32
93	No significant association between brain-derived neurotrophic factor gene rs6265 and cognitive function in Japanese patients with schizophrenia. <i>Psychiatry Research</i> , 2014, 215, 803-805.	3.3	3
94	Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 343-354.	2.1	25
95	P4-193: COMBINATION THERAPY WITH CHOLINESTERASE INHIBITORS AND MEMANTINE FOR ALZHEIMER'S DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS. , 2014, 10, P859-P860.		17
96	Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 633-641.	3.2	15
97	The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 105-118.	3.2	96
98	Efficacy and tolerability of clozapine in Japanese patients with treatment-resistant schizophrenia: Results from a 12-week, flexible dose study using raters masked to antipsychotic choice. <i>Asian Journal of Psychiatry</i> , 2013, 6, 200-207.	2.0	21
99	Efficacy and Tolerability of Perospirone in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>CNS Drugs</i> , 2013, 27, 731-741.	5.9	15
100	Blonanserin for schizophrenia: Systematic review and meta-analysis of double-blind, randomized, controlled trials. <i>Journal of Psychiatric Research</i> , 2013, 47, 149-154.	3.1	50
101	Yokukansan in the treatment of behavioral and psychological symptoms of dementia: a systematic review and meta-analysis of randomized controlled trials. <i>Human Psychopharmacology</i> , 2013, 28, 80-86.	1.5	91
102	Efficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia: An updated meta-analysis of randomized placebo-controlled trials. <i>Journal of Psychiatric Research</i> , 2013, 47, 2018-2020.	3.1	20
103	NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials. <i>Journal of Psychiatric Research</i> , 2013, 47, 1143-1149.	3.1	49
104	Efficacy and safety of noradrenalin reuptake inhibitor augmentation therapy for schizophrenia: A meta-analysis of double-blind randomized placebo-controlled trials. <i>Journal of Psychiatric Research</i> , 2013, 47, 1557-1563.	3.1	10
105	Efficacy and tolerability of high dose olanzapine in Japanese patients with treatment-resistant schizophrenia. <i>Asian Journal of Psychiatry</i> , 2013, 6, 86-87.	2.0	5
106	Further evidence of an association between a genetic variant in BMP7 and treatment response to SSRIs in major depressive disorder. <i>Journal of Human Genetics</i> , 2013, 58, 568-569.	2.3	2
107	Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1259-1266.	2.1	27
108	Relationship between nicotine dependence and the endophenotype-related trait of cognitive function but not acoustic startle responses in Japanese patients with schizophrenia. <i>Human Psychopharmacology</i> , 2013, 28, 220-229.	1.5	4

#	ARTICLE	IF	CITATIONS
109	Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 781.	2.2	5
110	GTP cyclohydrolase 1 gene haplotypes as predictors of SSRI response in Japanese patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2012, 142, 315-322.	4.1	10
111	Association between insertion/deletion polymorphism in angiotensin-converting enzyme gene and acute lung injury/acute respiratory distress syndrome: a meta-analysis. <i>BMC Medical Genetics</i> , 2012, 13, 76.	2.1	37
112	The Relationship Between Acoustic Startle Response Measures and Cognitive Functions in Japanese Patients with Schizophrenia. <i>NeuroMolecular Medicine</i> , 2012, 14, 131-138.	3.4	9
113	Serotonin 6 receptor gene and schizophrenia: case-control study and meta-analysis. <i>Human Psychopharmacology</i> , 2012, 27, 63-69.	1.5	6
114	Genome-Wide Association Study of Schizophrenia in a Japanese Population. <i>Biological Psychiatry</i> , 2011, 69, 472-478.	1.3	152
115	The <i>CLOCK</i> Gene and Mood Disorders: A Case-Control Study and Meta-analysis. <i>Chronobiology International</i> , 2011, 28, 825-833.	2.0	38
116	Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population. <i>Drug and Alcohol Dependence</i> , 2011, 113, 1-7.	3.2	11
117	Lack of association between translin-associated factor X gene (TSNAX) and methamphetamine dependence in the Japanese population. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1618-1622.	4.8	3
118	Serotonin 1A receptor gene, schizophrenia and bipolar disorder: An association study and meta-analysis. <i>Psychiatry Research</i> , 2011, 185, 20-26.	3.3	42
119	Possible association between ubiquitin-specific peptidase 46 gene and major depressive disorders in the Japanese population. <i>Journal of Affective Disorders</i> , 2011, 133, 150-157.	4.1	21
120	No significant association between <i>SIRT1</i> gene and methamphetamine-induced psychosis in the Japanese population. <i>Human Psychopharmacology</i> , 2011, 26, 445-450.	1.5	6
121	Association Analysis of Nuclear Receptor Rev-erb Alpha Gene (NR1D1) and Japanese Methamphetamine Dependence. <i>Current Neuropharmacology</i> , 2011, 9, 129-132.	2.9	5
122	No Association Between GRM3 and Japanese Methamphetamine- Induced Psychosis. <i>Current Neuropharmacology</i> , 2011, 9, 160-162.	2.9	1
123	Lack of Association Between Prokineticin 2 Gene and Japanese Methamphetamine Dependence. <i>Current Neuropharmacology</i> , 2011, 9, 133-136.	2.9	6
124	Genetic Association Analysis of NOS1 and Methamphetamine-Induced Psychosis Among Japanese. <i>Current Neuropharmacology</i> , 2011, 9, 155-159.	2.9	2
125	Effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in Japanese chronic schizophrenia. <i>Psychopharmacology</i> , 2010, 209, 185-190.	3.1	7
126	Translin-Associated Factor X Gene (TSNAX) may be Associated with Female major Depressive Disorder in the Japanese Population. <i>NeuroMolecular Medicine</i> , 2010, 12, 78-85.	3.4	14

#	ARTICLE	IF	CITATIONS
127	HTR2A is Associated with SSRI Response in Major Depressive Disorder in a Japanese Cohort. <i>NeuroMolecular Medicine</i> , 2010, 12, 237-242.	3.4	49
128	Lack of Association Between MAGEL2 and Schizophrenia and Mood Disorders in the Japanese Population. <i>NeuroMolecular Medicine</i> , 2010, 12, 285-291.	3.4	2
129	SIRT1 gene is associated with major depressive disorder in the Japanese population. <i>Journal of Affective Disorders</i> , 2010, 126, 167-173.	4.1	113
130	Pharmacogenetic study of serotonin 6 receptor gene with antidepressant response in major depressive disorder in the Japanese population. <i>Human Psychopharmacology</i> , 2010, 25, 481-486.	1.5	16
131	Genetic Association Analysis of Functional Polymorphisms in Neuronal Nitric Oxide Synthase 1 Gene <i><i>(NOS1)</i></i> and Mood Disorders and Fluvoxamine Response in Major Depressive Disorder in the Japanese Population. <i>Neuropsychobiology</i> , 2010, 61, 57-63.	1.9	24
132	Copy Number Variation in Schizophrenia in the Japanese Population. <i>Biological Psychiatry</i> , 2010, 67, 283-286.	1.3	102
133	Investigation of clinical factors influencing cognitive function in Japanese schizophrenia. <i>Neuroscience Research</i> , 2010, 66, 340-344.	1.9	24
134	Serotonin 6 receptor gene and mood disorders: Case"control study and meta-analysis. <i>Neuroscience Research</i> , 2010, 67, 250-255.	1.9	15
135	Association analysis of GRM2 and HTR2A with methamphetamine-induced psychosis and schizophrenia in the Japanese population. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 639-644.	4.8	25
136	PROKR2 is associated with methamphetamine dependence in the Japanese population. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 1033-1036.	4.8	15
137	Serotonin 1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients. <i>Neuropharmacology</i> , 2010, 58, 452-456.	4.1	29
138	Association analysis of SIGMAR1 with major depressive disorder and SSRI response. <i>Neuropharmacology</i> , 2010, 58, 1168-1173.	4.1	31
139	Orphan Nuclear Receptor Rev-erb Alpha Gene <i>(NR1D1)</i> and Fluvoxamine Response in Major Depressive Disorder in the Japanese Population. <i>Neuropsychobiology</i> , 2009, 59, 234-238.	1.9	10
140	Serotonin 1A receptor gene and major depressive disorder: an association study and meta-analysis. <i>Journal of Human Genetics</i> , 2009, 54, 629-633.	2.3	57
141	Association study of clock gene (CLOCK) and schizophrenia and mood disorders in the Japanese population. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 293-297.	3.2	77
142	CLOCK may Predict the Response to Fluvoxamine Treatment in Japanese Major Depressive Disorder Patients. <i>NeuroMolecular Medicine</i> , 2009, 11, 53-57.	3.4	44
143	Possible Association of Prokineticin 2 Receptor Gene (PROKR2) with Mood Disorders in the Japanese Population. <i>NeuroMolecular Medicine</i> , 2009, 11, 114-122.	3.4	42
144	No Association Between Polymorphisms of Neuronal Oxide Synthase 1 Gene (NOS1) and Schizophrenia in a Japanese Population. <i>NeuroMolecular Medicine</i> , 2009, 11, 123-127.	3.4	20

#	ARTICLE	IF	CITATIONS
145	Association analysis of Group II metabotropic glutamate receptor genes (GRM2 and GRM3) with mood disorders and fluvoxamine response in a Japanese population. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 875-879.	4.8	32
146	A functional polymorphism in estrogen receptor alpha gene is associated with Japanese methamphetamine induced psychosis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 895-898.	4.8	20
147	Genetic association analysis of serotonin 2A receptor gene (HTR2A) with bipolar disorder and major depressive disorder in the Japanese population. <i>Neuroscience Research</i> , 2009, 64, 231-234.	1.9	33
148	Prepulse inhibition of the startle response with chronic schizophrenia: A replication study. <i>Neuroscience Research</i> , 2009, 65, 259-262.	1.9	46
149	Meta-analysis of association between genetic variants in COMT and schizophrenia: An update. <i>Schizophrenia Research</i> , 2009, 110, 140-148.	2.0	114
150	BDNF is not associated with schizophrenia: Data from a Japanese population study and meta-analysis. <i>Schizophrenia Research</i> , 2009, 112, 72-79.	2.0	57
151	Association analysis of functional polymorphism in estrogen receptor alpha gene with schizophrenia and mood disorders in the Japanese population. <i>Psychiatric Genetics</i> , 2009, 19, 217-218.	1.1	7
152	Genetic association analysis of tagging SNPs in alpha4 and beta2 subunits of neuronal nicotinic acetylcholine receptor genes (CHRNA4 and CHRN2) with schizophrenia in the Japanese population. <i>Journal of Neural Transmission</i> , 2008, 115, 1457-1461.	2.8	11
153	No association between prostate apoptosis response 4 gene (PAWR) in schizophrenia and mood disorders in a Japanese population. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 531-534.	1.7	13
154	Glutamate Cysteine Ligase Modifier (GCLM) Subunit Gene Is Not Associated with Methamphetamine Use Disorder or Schizophrenia in the Japanese Population. <i>Annals of the New York Academy of Sciences</i> , 2008, 1139, 63-69.	3.8	16
155	Alpha4 and Beta2 Subunits of Neuronal Nicotinic Acetylcholine Receptor Genes Are Not Associated with Methamphetamine Use Disorder in the Japanese Population. <i>Annals of the New York Academy of Sciences</i> , 2008, 1139, 70-82.	3.8	15
156	Prostate Apoptosis Response 4 Gene Is Not Associated with Methamphetamine Use Disorder in the Japanese Population. <i>Annals of the New York Academy of Sciences</i> , 2008, 1139, 83-88.	3.8	5
157	Association analysis of nuclear receptor Rev-erb alpha gene (NR1D1) with mood disorders in the Japanese population. <i>Neuroscience Research</i> , 2008, 62, 211-215.	1.9	62
158	Clinical Investigation of Accumulation Process of ^{99m} Tc-HMDP and ^{99m} Tc-MDP in Bone. <i>Radioisotopes</i> , 2000, 49, 292-297.	0.2	2